Publication details
Extraoral manifastation of bisphosphonate induced osteonecrosis
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Conference abstract |
| Citation | |
| Description | Bisphosphonates (BP) are widely used in the management of metastatic bone disease and in the treatment of osteoporosis or Paget’s disease. The association between BP treatment and osteonecrosis of the jaw has been first described by Marx in 2003. He noted growing number of patients on long-term BP therapy with necrotic lesions in jaws . Majority of bone defects are preceded by previous trauma (usually dental treatment). In Ruggiero’s study, 14% of patients, however, had no history of recent dentoalveolar procedure and nevertheless presented with spontaneous exposure and necrosis of alveolar bones. This clinical scenario was previously seen only in patients after radiation therapy when radiotherapy fields included oral cavity. The BP-associated osteonecrosis of the jaw (BPOJ) was marked as an adverse effect of the BP therapy by remediation commission in the United States. Although the jaw is the most common manifestation of the BP osteonecrosis, a few authors described other affected sites. Whyte et al. treated a patient with BP-induced osteonecrosis of the hip. Extraoral bisphosphonates induced osteoncrosis is very rare phenomena, thus proper diagnosis may be chalenging. In cases of exposed bone, or unclear fractures in pacients recieving BP mast be this posibility considered. |